Novel Presentation of Terminal Ileitis Associated with Secukinumab Therapy.

Document Type

Article

Publication Date

9-28-2021

Publication Title

Case Reports in Gastrointestinal Medicine

Abstract

Inflammatory bowel disease (IBD) and psoriasis are chronic inflammatory immune-mediated diseases. The interleukin-23- (IL23-) T helper (Th)17 pathway has been implicated in their pathogenesis, with multiple biologic therapies targeting this pathway. IL-17, the main proinflammatory cytokine produced by (TH)17, has been targeted by antibodies and IL-17 receptor blockers with favorable outcomes in treating psoriasis and psoriatic arthritis. However, their role in IBD is unpredictable as studies reported worsening of IBD with agents targeting IL-17 and rare case reports with new-onset IBD. We present a case of Crohn's-like severe terminal ileitis and worsening diverticulitis complicated by intestinal perforation requiring total parenteral nutrition shortly after being started on secukinumab.

Volume

2021

First Page

5213876

Last Page

5213876

DOI

10.1155/2021/5213876

ISSN

2090-6528

PubMed ID

34621550

Link to Full Text

Share

COinS